Subretinal delivery of AAV5-mediated human Pde6b gene ameliorates the disease phenotype in a rat model of retinitis pigmentosa.

A genetic disorder that affects the beta subunit of cyclic guanosine monophosphate-phosphodiesterase type 6 (PDE6B) in humans leads to autosomal recessive retinitis pigmentosa (RP). This condition causes severe vision loss in early life due to fast deterioration of photoreceptors. This study evaluated the therapeutic potential of subretinal delivery of the adeno-associated virus (AAV)5-mediated human Pde6b gene in an RP rat model caused by Pde6b gene knockout (KO). We compared the transduction efficiency and tropism of different AAV serotypes (2, 5 and 8) in Pde6b KO rats and found that AAV5 had the highest and most specific expression in photoreceptors. We injected AAV5-Pde6b into the subretinal space of Pde6b KO rats on postnatal day 21. We assessed the protective effects six weeks postinjection by measuring PDE6B protein expression, photoreceptor structure, retinal morphology and thickness, retinal pigment epithelium integrity and visual function. AAV5-Pde6b treatment ameliorated the disease phenotype in Pde6b KO rats by restoring PDE6B protein expression, preserving photoreceptor structure, improving retinal morphology and thickness, and maintaining retinal pigment epithelium integrity. Functional analysis of vision by scotopic electroretinogram (ERG) and optokinetic nystagmus revealed that AAV5-Pde6b treatment significantly improved the visual function of Pde6b gene KO rats compared with AAV5-GFP-injected Pde6b KO rats. Our results demonstrate that AAV5-Pde6b may be a potential therapeutic gene candidate for RP caused by Pde6b mutations.